Laminar Pharmaceuticals

Executive Summary

Laminar Pharmaceuticals is a Spanish biopharmaceutical company pioneering Membrane Lipid Therapy (MELItherapy), a novel approach that targets membrane lipids instead of proteins or DNA to treat diseases with high unmet medical needs. Founded in 2011 and headquartered in Barcelona, the company is advancing first-in-class treatments for glioblastoma and Alzheimer's disease. Its lead candidate is a Phase 2 small molecule targeting glioblastoma, with a mechanism that disrupts lipid rafts to inhibit tumor growth. The Alzheimer's program is in earlier stages, aiming to modulate lipid pathways involved in neurodegeneration. The company's differentiated platform offers potential in oncology and neurology, areas where lipid-targeting therapies are underexplored. Key near-term milestones include Phase 2 data readout for the glioblastoma candidate, which could validate the MELItherapy approach. Additionally, initiation of a Phase 2 trial for Alzheimer's is anticipated, along with possible strategic partnerships or non-dilutive funding to support clinical development. Laminar's focus on high-unmet-need indications and its innovative biology position it as an intriguing opportunity, albeit with typical early-stage risk.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for glioblastoma candidate40% success
• Q4 2026Initiation of Phase 2 trial for Alzheimer's disease program30% success
• H2 2026Announcement of strategic partnership or grant funding50% success